Agilent Technologies, Inc.
NYSE:AMedical - Diagnostics & Research
+$3.04 today
- Market cap
- $50.00B
- Beta
- 1.26
- P/E (TTM)
- 25.5
- EPS (TTM)
- $5.00
- Dividend yield
- 0.59%
Volume 2.48M
Average 2.24M
A Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Agilent Technologies, Inc.NYSE: A
Accumulated OCI · Q3 FY2026 · quarter ended Jul 2026
Accumulated OCI remains negative
Q3 FY2026 Accumulated OCI was -$233M, compared with -$283M a year earlier.
Context
- Accumulated OCI amounted to 1.7% of total assets at the end of Q3 FY2026, down 0.6 pp from a year earlier.
- Accumulated OCI grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +17.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (226M) USD
- Year-over-year change
- +25.9%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (226M) | +25.9% |
| FY2024 | 2024-10-31 | (305M) | +6.7% |
| FY2023 | 2023-10-31 | (327M) | +5.8% |
| FY2022 | 2022-10-31 | (347M) | -23.0% |
| FY2021 | 2021-10-31 | (282M) | — |
Accumulated OCI vs competitors
How A compares with its peers on the latest reported figures
- A's Jul 2026 Accumulated OCI of -$233M is the 4th highest of the 9 companies compared; the peer median is -$263.93M.
- Its year-over-year change of +17.7% is the 3rd highest of 9, against a peer median of -23.0%.
- Accumulated OCI amounts to 1.7% of total assets for A, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $0 | +100.0% | — | 0.0% | |
| Jun 2026 | -$96.8M | +0.2% | — | 1.6% | |
| Jul 2026 | -$166M | -42.2% | — | 0.7% | |
| Jul 2026 | -$233M | +17.7% | — | 1.7% | |
| Jul 2026 | -$256.55M | -62.9% | — | 2.1% | |
| Jun 2026 | -$271.3M | -76.1% | — | 2.6% | |
| Jun 2026 | -$320.7M | +23.9% | — | 8.7% | |
| Jun 2026 | -$402.67M | -3.9% | — | 6.8% | |
| Sep 2026 | -$865M | -46.6% | — | 0.9% | |
| Peer median (excluding A) | -$263.93M | -23.0% | — | 1.9% | |
Competitors are the stored peer set for A. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.48B | 1.05B | 1.59B | 1.33B | 1.79B |
| Short-term Investments | 91M | 0 | 0 | 0 | 0 |
| Net Receivables | 1.17B | 1.41B | 1.29B | 1.32B | 1.49B |
| Inventory | 830M | 1.04B | 1.03B | 991M | 1.03B |
| Other Current Assets | 222M | 282M | 274M | 315M | 293M |
| Total Current Assets | 3.8B | 3.78B | 4.19B | 3.96B | 4.59B |
| Property, Plant & Equipment (Net) | 945M | 1.1B | 1.42B | 1.96B | 2.02B |
| Goodwill | 3.98B | 3.95B | 3.96B | 4.47B | 4.47B |
| Intangible Assets | 981M | 821M | 475M | 547M | 445M |
| Long-term Investments | 185M | 195M | 164M | 175M | 133M |
| Tax Assets | 0 | 0 | 0 | 436M | 0 |
| Other Non-current Assets | 820M | 686M | 554M | 297M | 1.06B |
| Total Non-current Assets | 6.91B | 6.75B | 6.58B | 7.89B | 8.13B |
| Total Assets | 10.71B | 10.53B | 10.76B | 11.85B | 12.73B |
| Account Payables | 446M | 580M | 418M | 540M | 570M |
| Short-term Debt | 0 | 36M | 0 | 45M | 304M |
| Tax Payables | 0 | 0 | 73M | 0 | 0 |
| Deferred Revenue | 441M | 461M | 505M | 544M | 624M |
| Other Current Liabilities | 493M | 455M | 371M | 326M | 443M |
| Total Current Liabilities | 1.71B | 1.86B | 1.6B | 1.9B | 2.35B |
| Long-term Debt | 2.73B | 2.73B | 2.74B | 3.35B | 3.05B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 879M | 633M | 580M | 566M | 589M |
| Total Non-current Liabilities | 3.61B | 3.37B | 3.32B | 4.05B | 3.64B |
| Total Liabilities | 5.32B | 5.23B | 4.92B | 5.95B | 5.99B |
| Common Stock | 3M | 3M | 3M | 3M | 3M |
| Retained Earnings | 348M | 324M | 782M | 750M | 1.39B |
| Accumulated OCI | (282M) | (347M) | (327M) | (305M) | (226M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 5.39B | 5.31B | 5.85B | 5.9B | 6.74B |
| Total Debt | 2.73B | 2.77B | 2.74B | 3.57B | 3.35B |
| Net Debt | 1.25B | 1.72B | 1.15B | 2.25B | 1.57B |
Agilent Technologies, Inc.
NYSE:A
Intrinsic Alpha fair value
Locked
Current Price
$177.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.